New cocktail of drugs shows promise for tough bile duct cancer
NCT ID NCT05668884
First seen Jan 26, 2026 · Last updated Jun 23, 2026 · Updated 20 times
Summary
This phase 2 trial is testing a combination of four drugs—two chemotherapy drugs (gemcitabine and oxaliplatin), a targeted therapy (donafenib), and an immunotherapy (tislelizumab)—in 93 people with advanced biliary tract cancer that has spread. The goal is to see if this mix can shrink tumors and improve survival. Participants must be in fairly good health and have measurable tumors. The study is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200062, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gemcitabine, Oxaliplatin, Donafenib, and Tislelizumab
What this could lead to
If successful, this combination could offer a new treatment option that shrinks tumors and delays cancer progression in people with advanced biliary tract cancer.
What could go wrong
This is an early phase 2 trial with only 93 participants, so results may not apply to everyone. The combination of four drugs may cause significant side effects, and it is not yet known if it works better than standard treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.